What happened with WVE today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Wave Life Sciences, Inc., since renamed Wave Life Sciences Ltd., develops medicines designed to treat disease by editing RNA or changing how it controls protein production. Its PRISM platform helps it design these medicines, which are still in development and clinical testing; it has no marketed products or product-sales revenue.
GSK pays Wave to investigate biological targets for potential medicines. It prepays the costs of target-validation work and makes additional payments when it selects programs to advance toward drug candidates. Wave’s revenue now comes entirely from GSK, making the collaboration and GSK’s decisions about advancing programs central to the business.
Wave also relies on raising capital, principally through share offerings, to fund development. Selling medicines will require successful clinical testing and regulatory approval; its candidates cannot be marketed before the relevant approvals are obtained.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Wave's prospects also hinge on competing with Arrowhead Pharmaceuticals, absent from this list, which develops RNA medicines for AATD and obesity.
Human evidence that Korro Bio's RNA-editing medicines are safe and effective would also inform Wave's platform: both develop short synthetic strands, or oligonucleotides, that use the body's ADAR enzymes to edit RNA. Korro says this approach is not yet clinically validated for human treatment, making that validation the key news to watch.
Clinical evidence from ProQR Therapeutics matters to Wave because both use short synthetic strands to edit RNA as a treatment. Watch ProQR's Axiomer programs for evidence that recruiting the body's ADAR enzymes can change disease-related RNA without changing DNA.
Beam Therapeutics offers a competing path for treating alpha-1 antitrypsin deficiency (AATD): it edits DNA bases, while Wave edits RNA. Watch the efficacy, safety and convenience of Beam's AATD treatment, factors Beam identifies as central to competition.
Sarepta's marketed VYONDYS 53 directly competes with Wave's WVE-N531 for Duchenne muscular dystrophy patients whose mutations allow exon 53 skipping—leaving out that section of the RNA instructions to make a shortened, functional dystrophin protein. Watch VYONDYS 53 specifically, rather than Sarepta's total product sales, which do not separate this patient group.
uniQure's Huntington's disease gene therapy competes with Wave's treatment using short strands that act on RNA, an antisense approach. Its Huntington's results are the relevant comparison, with Wave's WVE-003 targeting a genetic marker estimated to occur in about 40% of Huntington's patients.
Wave depends on GSK's payments for RNA-medicine research and development: the collaboration generated all $42.7 million of Wave's 2025 revenue. Watch GSK's decisions to advance programs, as its selection of four programs after target validation brought additional payments to Wave.
Ionis Pharmaceuticals competes with Wave in medicines made from short synthetic strands that act on RNA, including Huntington's disease programs. Watch its Huntington's development results; the supplied filing says no treatment is approved to delay the disease's onset or slow its progression.
Alnylam competes with Wave in chemically synthesized medicines that silence RNA, including Huntington's disease treatments. Its RNA-silencing and delivery advances matter when judging Wave's SpiNA platform, whose cited potency and durability results come from mouse studies.
Entrada Therapeutics competes with Wave to restore functional dystrophin in Duchenne muscular dystrophy by using short synthetic strands to skip sections of RNA instructions. Watch Entrada's programs for exons 44, 45, 50 and 51, while keeping their mutation groups separate from Wave's exon-53 candidate WVE-N531.
Prime Medicine's DNA-editing program for alpha-1 antitrypsin deficiency competes with Wave's RNA-editing treatment for the same disease. Watch its wholly owned liver-disease program for AATD, rather than its separate work editing T cells for BMS.
ADARx competes with Wave in obesity medicines using small interfering RNA, or siRNA, to reduce production of target proteins. Watch ADARx's fat-tissue program, which is among its extrahepatic candidates in or advancing toward studies needed before human trials—not its more advanced liver programs.
PTC Therapeutics competes with Wave on two fronts: it sells DMD medicines and develops a Huntington's program that changes how RNA sections are joined, known as splicing. Watch Translarna and Emflaza in DMD and its Huntington's splicing program separately, since they challenge different Wave candidates.
Silence Therapeutics and Wave both need their RNA-silencing medicines to reach liver cells effectively and keep working; both use chemically modified siRNA linked to GalNAc for liver targeting. Watch how strongly and durably Silence's mRNAi GOLD candidates silence their targets, the same delivery challenge facing Wave's liver-directed siRNA.
GSK plc earningsGSK
If GSK’s report discusses its RNA-medicine programs with Wave, it can show whether the partner is advancing work that could bring Wave additional payments.
Look for any disclosure that a Wave collaboration program is moving into the next stage of development. Advancement could create an opportunity for additional payments to Wave, but it does not mean Wave has recognized revenue. No reported progress would leave less evidence of the collaboration moving forward, not prove that collaboration revenue is zero.
Ionis Pharmaceuticals, Inc. earningsIONS
If Ionis reports progress in its Huntington’s disease program, its report will show how another oligonucleotide developer is advancing a treatment for the same disease as Wave’s WVE-003.
Look for clinical progress or setbacks in Ionis’s Huntington’s program. Progress would show that an oligonucleotide treatment for the disease can move forward, but would not prove that Wave’s WVE-003 works; a setback would add uncertainty to the treatment path. WVE-003 also targets a genetic marker estimated to occur in about 40% of patients, so the two programs are not identical.
Sarepta Therapeutics,, Inc. earningsSRPT
If Sarepta reports VYONDYS 53 sales or use, its report can show how demand is changing for a marketed treatment that competes with Wave’s WVE-N531 for the same patient group.
Look for sales or use of VYONDYS 53 itself, not Sarepta’s total product sales, which do not isolate demand from this patient group. Stronger VYONDYS 53 figures would show that these patients are using an approved treatment, making competition for Wave’s WVE-N531 more tangible. Weaker figures could point to less demand for this option, but would not establish that Wave’s candidate works.
Silence Therapeutics Plc earningsSLN
If Silence reports on its liver-targeted siRNA medicines, its results can show whether the delivery approach it shares with Wave can keep a target’s production suppressed.
Look for whether Silence’s candidates suppress their target messenger RNA—the instructions cells use to make proteins—strongly and for a sustained period. Strong, durable effects would show that GalNAc-based liver targeting works in its programs and raise the standard Wave’s liver-directed siRNA must meet. Weak or short-lived effects would leave the delivery challenge unresolved, but would not prove Wave’s candidates will fail.
ProQR Therapeutics N.V. earningsPRQR
If ProQR reports human evidence from its Axiomer programs, its report can show whether recruiting the body’s ADAR enzymes to edit RNA is gaining clinical support—a scientific approach Wave also pursues.
Look for human data from Axiomer showing whether disease-related RNA changed as intended and whether safety concerns emerged. Convincing evidence would be an important step toward clinical validation of an RNA-editing approach relevant to Wave’s platform. Unclear effects or safety issues would leave a key hurdle unresolved; ProQR’s results would not directly prove whether Wave’s treatment works.
Wave Life Sciences Ltd. earningsThis company
Wave has no product sales and relies on revenue recognized under its GSK collaboration, so this report shows how that income compares with research costs and cash use.
Read collaboration revenue alongside research spending and cash used in operations. Revenue is recognized for work performed and milestones; it is not the same as cash received in the quarter. If collaboration revenue rises relative to research costs while operating cash use stays controlled, GSK is covering more of the development burden. If revenue falls as costs and cash use rise, Wave must rely more on its cash reserves and future funding to advance its pipeline.
